Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Dyne Therapeutics, Inc. (DYN)

On September 3, 2024, Dyne issued a press release titled “Announcement[ing] new clinical data from the ongoing Phase 1/2 DELIVER study of DYNE-251 in patients with exon 51 skipping-susceptible Duchenne muscular dystrophy (DMD), demonstrating unprecedented dystrophin expression and functional improvement across multiple cohorts.” In a separate press release on the same day, Dyne announced that the company’s Chief Medical Officer, Chief Operating Officer and Chief Business Officer “Step[ping] resigned from their roles.” On this news, Dyne’s stock price fell by $14.15 per share, or approximately 30.7%, from $46.09 on August 30, 2024 to $31.94 per share on September 3, 2024.

If you purchased or otherwise acquired Dyne securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected] or by completing this CONTACT FORM to discuss your rights or interests with respect to these matters free of charge.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm focused on securities, antitrust, whistleblower and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in billions of dollars in awards.

This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and professional rules.

View original version on businesswire.com:

Dyne Therapeutics stock at the time of publication of the news with a decline of -1.61 % up to 32.47USD on the Nasdaq stock exchange (September 9, 2024, 11:20 p.m.).